Case report
Open access
Sep 2026
Successful Conversion Surgery after S-1 plus oxaliplatin Plus Zolbetuximab for Initially Unresectable Gastric Cancer with Pancreatic Invasion: A Case Report
ABSTRACT INTRODUCTION Zolbetuximab, a monoclonal antibody targeting claudin 18.2 (CLDN18.2), has recently demonstrated significant survival benefits when combined with chemotherapy for advanced gastric cancer. However, evidence regarding conversion surgery following SOX plus zolbetuximab therapy remains extremely limit...
Yuma Fuse, H. Ono, Masanori Eguchi et al.
· Surgery Case Reports · 0 citations